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After its first application in 1831, during the second cholera 
pandemic (1), “normal” saline has become one of the most 
commonly used crystalloid solutions worldwide (2) and over 
one million litres are administered intravenously everyday (1). 
Nevertheless, the non-physiological composition of the 
0.9% saline and its related risks of kidney injury have 
recently alarmed intensivists and other clinicians and the 
so called “balanced crystalloids” have been studied as 
safer alternatives. On this regard, the German guidelines 
on “Intravascular Volume Therapy in Adults”, recently 
published in the European Journal of Anaesthesia (3), 
addressed the “Differences between crystalloids in Intensive 
Care Unit (ICU) Patients”. With an “A” Grade of 
Recommendation (strong) it has been indicated that “An 
isotonic saline (i.e., NaCl 0.9%) solution must not be used as 
a volume substitute in intensive care medicine” (3). In the 
background section, the authors underline that balanced 
crystalloid solutions are associated with a lower incidence 
of hyperchloremic acidosis and lower renal dysfunction in 
comparison with isotonic saline. In support of this statement, 
two studies are cited: the first is a single-centre, two-arm, 
double-blind, randomized trial performed in 42 patients 
with traumatic brain injury or subarachnoid hemorrhage 
that showed a 95% incidence of hyperchloremic acidosis in 
the saline group vs. 65% in the balanced group after 5,000 
mL in both groups over 48 hours (hazard ratio =0.28; 95% 
CI: 0.11, 0.70; P=0.006) (4). The second study, by Yunos et 
al. has been published in the Journal of American Medical 
Association in 2012 (5). It is a prospective open-label 
before and after pilot study on about 1,400 patients that 
demonstrated that treatment with chloride-rich solutions 
(0.9% saline, 4% succinylated gelatin solution, or 4% 
albumin solution) was associated with a significantly higher 
serum creatinine level (P=0.03), an increase in the incidence 
of renal insufficiency (P<0.001) and a greater need for renal 
replacement therapy (RRT) (P=0.004) in comparison with 
the time-period when chloride-poor solutions (balanced 
solutions or chloride-poor 20% albumin) were administered, 
after adjustment for multiple covariates (5).
With this background, safety concerns arose about 
the use of saline in critically ill patients and other non-
randomized studies and meta-analyses seemed to confirm 
that high chloride content of saline may contribute to the 
development of acute kidney injury (AKI), increase the 
need for RRT, and even rise the mortality rate (6,7). In 
light of these effects on renal function, balanced solutions 
with lower, more physiologic chloride concentration, have 
been suggested (1,4). In order to fill this significant gap 
in scientific literature, Young et al. recently published a 
double-blind, cluster randomized, double-crossover trial (8) 
(Saline versus Plasma-Lyte® 148 for ICU fluid Therapy, 
SPLIT, trial) on 2,278 patients admitted to 4 general 
medical and surgical ICUs (one of them mainly admitted 
patients with cardiothoracic and vascular diseases) requiring 
crystalloid fluid therapy. Patients randomly received either 
buffered crystalloid (Plasma-Lyte 148®; B-group; 1152 
patients) or saline (NaCl 0.9%; S-group; 1110 patients), 
according to clinical indication, as maintenance therapy 
or fluid volume replacement. The trial was specifically 
designed to evaluate the proportion of patients with 
AKI (serum creatinine level rise of at least 2-fold or a 
serum creatinine level of ≥3.96 mg/dL with an increase 
of ≥0.5 mg/dL) as primary outcome, RRT use, change 
in serum creatinine (∆ creatinine), need for and duration 
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of mechanical ventilation, ICU readmission, ICU length 
of stay, and ICU and in-hospital mortality as secondary 
outcomes. Surprisingly, the use of a buffered crystalloid 
compared with saline did not reduce the risk of AKI (9.6% 
of B-group patients vs. 9.2% of S-group patients; P=0.77) 
at 90-day follow-up. In addition, no significant between-
group differences were observed in any of the secondary 
outcomes.
This well conducted trial should be carefully appraised 
before reaching any “new” conclusion or recommendation 
for the clinicians, in order to avoid any confusion 
and apparent uncertainty on the effects of fluid type 
administration.
First, both groups had few comorbidities and overall 
patients’  outcomes, regardless of the randomized 
intervention, was unlikely representative of many ICUs case 
mix. The Acute Physiology and Chronic Health Evaluation 
II score was 14.1 in both groups, the ICU mortality was 
6.6 and 7.2% and the RRT rates 3.3 and 3.4% in B and 
S-groups, respectively. As a demonstration of the low-
severity of illness, Hoste and co-workers, in a recent 
epidemiologic study (Acute Kidney Injury-Epidemiologic 
Prospective Investigation; AKI-EPI) found that in 33 
different countries on five continents and 97 ICUs, 
out of 1,802 patients, 57.3 % had AKI, 23.5 % of them 
received RRT, and 13.5 of all patients received RRT (9), a 
significantly higher incidence than in Young et al.’s study. 
As far as the case mix of enrolled patients is concerned, 
furthermore, most patients of the SPLIT trial underwent 
cardiothoracic and vascular surgeries. Post-surgical patients 
may be very different from critically ill patients with 
multiple organ failure in which many nephrotoxic factors 
(e.g., anemia, hypotension, vasopressors, nephrotoxic 
antibiotics etc.) may co-act significantly increasing the 
risk of AKI (10). Specifically, use of contrast media and 
nephrotoxic drugs (e.g., vancomycin or aminoglycosides), 
independent predictors of nephrotoxicity in the critically ill, 
were not evaluated in the SPLIT trial (8).
Secondly, the median administered volume of each 
fluid was low quite low (about 2,000 mL in both the B and 
S-groups; P=0.63) during the ICU stay, and most of the 
fluid administration occurred during the first 24 hours as 
clearly underlined by the accompanying Editorial (11). In 
view of this observation, some general pathophysiological 
considerations should be highlighted: (I) the restricted fluid 
therapy, when adequately balanced between hypovolemia 
and excessive weight gain, has shown to be, per se, useful 
in reducing AKI incidence (12)—this approach, carefully 
applied in Young’s study might have somehow blunted the 
negative effects of the nephrotoxic fluid; (II) the possibility of 
infusing low volumes of fluids may indirectly confirm the low 
severity of illness of enrolled patients and a good integrity 
of the endothelial glycocalix and microcirculation (13)— 
this is generally not the case in conditions of severe 
inflammatory states (e.g., sepsis); (III) the development 
of metabolic acidosis [also described as hyperchloremic 
acidosis or strong ion difference acidosis (14)], as well as the 
decrease in kidney cortical perfusion were demonstrated 
after rapid administration (bolus) of 2,000 mL of saline in 
healthy subjects (15,16) or after 70 mL/Kg in 2 hrs after 
surgery (17). Toxicity, in general, is dose dependent and the 
consequences of the exposure depend on the susceptibility 
of the patients, as for all the other substances present in 
nature, water included (18). Serum chloride concentrations 
were not reported in the study by Young and colleagues (6). 
Therefore, it could be argued that the negative (mainly 
renal) effects of chloride loading might be more pronounced, 
and therefore easier to be demonstrated, in sicker patients, 
with more limited renal functional reserve, who receive 
larger chloride amounts with replacement fluids. In other 
words, the only fact that I prepare a cake with lowest doses 
of a toxic substance without causing gastro-enteritis to 
people who taste it, does not necessarily mean that this 
receipt is safe. 
Third, in the SPLIT trial,  the renal injury was 
investigated with serum creatinine levels only, according to 
RIFLE and KDIGO criteria. Possibly, although the SPLIT 
trial has been specifically designed to test the effects of two 
different fluid preparations on renal function, the authors 
did not investigate subclinical forms of renal dysfunction 
that might be induced by chloride-rich solutions (19). It 
is well known that the so called renal functional reserve, 
in healthy subjects, must be exhausted before serum 
creatinine increases (11,20). Since creatinine has a much 
lower sensitivity than other recently identified biomarkers, 
it could be supposed that different methods of investigation, 
could have revealed renal reserve reduction, otherwise 
missed by the simple creatinine rise (21). In fact, some novel 
biomarkers appear to be positive even in to “subclinical 
AKI” where creatinine does not increase (22,23). Moreover, 
the RIFLE classification also includes urine output criteria, 
that has not been included in the SPLIT trial. The only 
use of serum creatinine alone has shown to potentially 
underestimate the incidence and grade of AKI and delay the 
diagnosis in critically ill adult patients (10).
As a final consideration, however, it must be remarked 
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that the SPLIT trial clearly provided some support on the 
fact that the administration of a relatively low volume of 
0.9% saline to low/moderate risk ICU patients, does not 
cause clinically significant, or demonstrable, harm.
Conclusions
Fluids are the most frequent therapy administered to critically 
ill patients as for rehydration, as a carrier for medications, 
and as volume expander for hemodynamic optimization. 
Nonetheless, which is the best fluid composition is still an 
unsolved debate and there is a wide variation in clinical 
practice with respect to the selection of resuscitation fluids (2). 
Undoubtedly, large-scale randomized trials are still required 
to demonstrate which crystalloid solution is superior over the 
other in specific clinical conditions. What should always be 
considered with great attention is whether are we justified, 
in the absence of specific electrolyte deficit (i.e., sodium or 
chloride), to administer a non-physiologic fluid that likely 
causes harm even if not clinically or laboratory visible. Since 
safer alternatives exist, in the need of administering large 
volumes of fluids to critically ill patients, 0.9% saline should 
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